Head to Head Analysis: Cardio Diagnostics (NASDAQ:CDIO) & TNF Pharmaceuticals (NASDAQ:TNFA)

Cardio Diagnostics (NASDAQ:CDIO) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Cardio Diagnostics and TNF Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$34,890.00	567.63	-$8.38 million	N/A	N/A
TNF Pharmaceuticals	N/A	N/A	-$4.00 million	N/A	N/A

TNF Pharmaceuticals has lower revenue, but higher earnings than Cardio Diagnostics.

Risk and Volatility

Cardio Diagnostics has a beta of 3.61, meaning that its stock price is 261% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500.

Profitability

This table compares Cardio Diagnostics and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-22,732.03%	-258.85%	-191.20%
TNF Pharmaceuticals	N/A	-180.71%	-84.27%

Analyst Ratings

This is a summary of recent ratings and target prices for Cardio Diagnostics and TNF Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0	0	1	0	3.00
TNF Pharmaceuticals	0	0	0	0	0.00

Cardio Diagnostics presently has a consensus price target of $2.00, indicating a potential upside of 426.59%. Given Cardio Diagnostics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Cardio Diagnostics is more favorable than TNF Pharmaceuticals.

Insider & Institutional Ownership

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 1.2% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cardio Diagnostics beats TNF Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.